Debapriya Basu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Debapriya Basu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Suvro Sankha Datta
Department of Transfusion Medicine, Tata Medical Center, Newtown, Kolkata, India
9 shared publications - Durba Biswas
Department of Transfusion Medicine, Tata Medical Center, Kolkata, India
6 shared publications - Sabita Basu
Department of Transfusion Medicine, Tata Medical Center, Kolkata, India
4 shared publications - Ayesha Sinha
Department of Transfusion Medicine, Tata Medical Center, Kolkata, India
3 shared publications - Najla Haneefa Basheela
Department of Transfusion Medicine, Tata Medical Center, Kolkata, India
3 shared publications Joydeep Roy
Department of Transfusion Medicine, Tata Medical Center, Kolkata, West Bengal, India
2 shared publications
Latest Publications
- 10 March 2026
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 65 (3) , 104425
Distinguishing patients with suspected auto- versus allo-anti-Jka antibodies and highlighting the clinical significance: A case series from India
- 10 March 2026
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 65 (3) , 104425
Distinguishing patients with suspected auto- versus allo-anti-Jka antibodies and highlighting the clinical significance: A case series from India
- 6 April 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (3) , 104116
Weak D testing might be discontinued for RhD-negative blood donors with C and E negative phenotypes in the Indian population
- 6 April 2025
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 64 (3) , 104116
Weak D testing might be discontinued for RhD-negative blood donors with C and E negative phenotypes in the Indian population
- 25 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 1-5
Direct Antiglobulin Test Positivity in Blood Donors and Impact on Donor Health and Transfusion Services: A Seven-Year Retrospective Study from Eastern India
The aim of this study is to determine the incidence of a positive direct antiglobulin test (DAT) in a population of blood donors in Eastern India and to explore the impact of DAT positivity on donor health and transfusion services. We conducted a retrospective study on 89,402 blood donors over a seven-year period (2018–2024). Positive DAT results were detected using the column agglutination technique (CAT) following a difficulty in the cross-match, a positive weak D test on donor RhD typing, and a positive autocontrol encountered during donor antibody screening. Furthermore, DAT was subclassified, and donors exhibiting a DAT strength of ≥ 2 + were recalled and investigated. We found the DAT was positive in 54 donors (0.06%) with an overall incidence of 1:1,656. The DAT-positive donors presented predominantly as crossmatch incompatibility (85.2%). The majority of blood donors (96.3%) were IgG positive. Of the 39 donors who were evaluated, two were found to have autoimmune diseases. The remaining donors showed no signs of hemolysis and were in good health. The incidence of positive DAT results in eastern Indian blood donors is higher, leading to increasing non-utilization of collected blood units. There is a need for a national policy for managing DAT-positive donors in India.
- 25 February 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (4) , 1-5
Direct Antiglobulin Test Positivity in Blood Donors and Impact on Donor Health and Transfusion Services: A Seven-Year Retrospective Study from Eastern India
The aim of this study is to determine the incidence of a positive direct antiglobulin test (DAT) in a population of blood donors in Eastern India and to explore the impact of DAT positivity on donor health and transfusion services. We conducted a retrospective study on 89,402 blood donors over a seven-year period (2018–2024). Positive DAT results were detected using the column agglutination technique (CAT) following a difficulty in the cross-match, a positive weak D test on donor RhD typing, and a positive autocontrol encountered during donor antibody screening. Furthermore, DAT was subclassified, and donors exhibiting a DAT strength of ≥ 2 + were recalled and investigated. We found the DAT was positive in 54 donors (0.06%) with an overall incidence of 1:1,656. The DAT-positive donors presented predominantly as crossmatch incompatibility (85.2%). The majority of blood donors (96.3%) were IgG positive. Of the 39 donors who were evaluated, two were found to have autoimmune diseases. The remaining donors showed no signs of hemolysis and were in good health. The incidence of positive DAT results in eastern Indian blood donors is higher, leading to increasing non-utilization of collected blood units. There is a need for a national policy for managing DAT-positive donors in India.
- Open Access
- 22 August 2024
- Published by Medknow in Asian Journal of Transfusion Science
- Vol. 20 (2) , 481-484
Clinical spectrum of anti-E: A thought for transfusion services
The rhesus system antigens are of immense clinical importance in transfusion medicine. They can stimulate the production of clinically significant antibodies. Anti-E is one of the most common alloantibodies reported in multi-transfused patients in India which is known to cause delayed hemolytic transfusion reaction and hemolytic disease of the fetus and newborn (HDFN). This antibody can have different clinical presentations and persist for a prolonged period in the plasma. In this case series, we report five such cases where anti-E antibodies were identified in different clinical settings. The clinical scenarios consist of HDFN, hematopoietic stem cell transplantation, and blood donors, where the anti-E antibody was detected during the immunohematological workup. The patients were managed according to the clinical spectrum of the antibody.
- 22 August 2024
- Published by Medknow in Asian Journal of Transfusion Science
- Vol. 20 (2) , 481-484
Open AccessClinical spectrum of anti-E: A thought for transfusion services
The rhesus system antigens are of immense clinical importance in transfusion medicine. They can stimulate the production of clinically significant antibodies. Anti-E is one of the most common alloantibodies reported in multi-transfused patients in India which is known to cause delayed hemolytic transfusion reaction and hemolytic disease of the fetus and newborn (HDFN). This antibody can have different clinical presentations and persist for a prolonged period in the plasma. In this case series, we report five such cases where anti-E antibodies were identified in different clinical settings. The clinical scenarios consist of HDFN, hematopoietic stem cell transplantation, and blood donors, where the anti-E antibody was detected during the immunohematological workup. The patients were managed according to the clinical spectrum of the antibody.
- 25 July 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (2) , 427-428
Red Cell Genotyping Helps in Managing a Multi-Transfused Patient with Serologically Inconclusive Results
- 25 July 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (2) , 427-428
Red Cell Genotyping Helps in Managing a Multi-Transfused Patient with Serologically Inconclusive Results
- 1 April 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (4) , 710-714
A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India
The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at the different pre-transfusion policies and the risk of erythrocyte alloimmunization. Patients receiving daratumumab from 2018 to 2023 were reviewed. They were divided into two groups: Group I, presented before administration of daratumumab, and Group II, presented after drug administration. Appropriate strategies were applied to mitigate the drug interference, and the transfusion outcome was analyzed by following up with the patients for six months. A total of 48 patients were studied. The antibody screen was negative in patients who presented before the administration of daratumumab (n = 35). Extended phenotyping was done for 31 patients. Blood group genotyping was done for 4 patients. The patients who presented after daratumumab administration (n = 13) had a positive antibody screen that became negative with dithiothreitol-treated cells. A total of 261 red cell units were transfused to these patients (mean 5.55 units per patient). None of the patients developed antibodies during the follow-up period. The transfusion services must frame policies and protocols to mitigate drug interference. Good communication between transfusion services and clinical hematologists is a must to ensure safe transfusions.
- 1 April 2024
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (4) , 710-714
A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India
The aim of this study is to analyze the profile of patients receiving daratumumab and their presentation to the transfusion laboratory by looking at the different pre-transfusion policies and the risk of erythrocyte alloimmunization. Patients receiving daratumumab from 2018 to 2023 were reviewed. They were divided into two groups: Group I, presented before administration of daratumumab, and Group II, presented after drug administration. Appropriate strategies were applied to mitigate the drug interference, and the transfusion outcome was analyzed by following up with the patients for six months. A total of 48 patients were studied. The antibody screen was negative in patients who presented before the administration of daratumumab (n = 35). Extended phenotyping was done for 31 patients. Blood group genotyping was done for 4 patients. The patients who presented after daratumumab administration (n = 13) had a positive antibody screen that became negative with dithiothreitol-treated cells. A total of 261 red cell units were transfused to these patients (mean 5.55 units per patient). None of the patients developed antibodies during the follow-up period. The transfusion services must frame policies and protocols to mitigate drug interference. Good communication between transfusion services and clinical hematologists is a must to ensure safe transfusions.
- 8 December 2023
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (2) , 359-361
Weakening of A Antigen in Myelodysplastic Syndrome-Mimicking a Case of Wrong Blood in Tube
- 8 December 2023
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (2) , 359-361
Weakening of A Antigen in Myelodysplastic Syndrome-Mimicking a Case of Wrong Blood in Tube
- 25 May 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 61 (6) , 103466
Are we missing reverse TRALI? – A real world experience from a tertiary care oncology centre in India
- 25 May 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 61 (6) , 103466
Are we missing reverse TRALI? – A real world experience from a tertiary care oncology centre in India
- 8 February 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 61 (4) , 103394
Screening of group O platelet donors for high-titer ABO antibodies- limitations, feasibility, and future
- 8 February 2022
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 61 (4) , 103394
Screening of group O platelet donors for high-titer ABO antibodies- limitations, feasibility, and future